==Aardvark Therapeutics (AARD) pauses Phase 3 Hunger Elimination or Reduction Objective trial

 

Aardvark Therapeutics pauses Phase 3 HERO trial of ARD-101 in Prader-Willi after cardiac findings as RBC, Stifel, Morgan Stanley, HC Wainwright cut ratings

• Pause followed reversible cardiac observations in an ARD-101 healthy volunteer study, which the company described as reversible.
• Pause delays HERO trial's topline data timeline for ARD-101 in Prader-Willi syndrome.
• RBC Capital, Stifel, Morgan Stanley and HC Wainwright downgraded Aardvark Monday and cut price targets to about $6–$7.